The promise of thrombopoietins in the treatment of ITP

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 6, 2005, Pages 464-466

  Kuter, David J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 531; ANTINEOPLASTIC AGENT; ELTROMBOPAG; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PEPTIDE DERIVATIVE; PLACEBO; RECOMBINANT CYTOKINE; RECOMBINANT THROMBOPOIETIN; STEROID; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NONHUMAN; QUALITY OF LIFE; SPLENECTOMY; THROMBOCYTE COUNT;

CARRIER PROTEINS; CLINICAL TRIALS, PHASE II; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; THROMBOPOIETIN;

EID: 26044443768     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457-3469.
2. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-3248.
3. Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol. 2001;68:210-214.
4. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002;100:728-730.
5. Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem. 2002;45:3576-3578.
6. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004; 76:628-638.
7. Kuter DJ, Bussel J, Aledort L, et al. A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel thrombopoietic protein (AMG 531) in thrombocytopenic adult patients with immune thrombocytopenic purpura. Blood. 2004;104:148a.